Building the intelligence layer for modern biotech
Contraview is developing ContraNova, an intelligent system that turns the noise of science into clear signals for action. We read papers, trials, patents, markets and company data so the AI can see where the field is moving and why it matters.
what we do
AI powered biotech intelligence
ContraNova brings clarity to how science becomes investment. The platform continuously analyzes publications, clinical evidence, patents and operating data to surface technologies that are actually moving the field forward. It gives investors and research leaders a clean view of what is working, what is slowing down and where value is forming.
The system learns from every new datapoint and validates against real outcomes. By combining predictive modeling with domain grounded reasoning, ContraNova helps capital flow to the discoveries that matter. The goal is a more open, efficient and evidence based biotech ecosystem.
our technology
How the engine works
ContraNova combines large language models, knowledge graphs and curated scientific datasets to reason across biology, clinical evidence and markets at once. Each model offers a different perspective and the system reconciles them into a single, transparent view.
The architecture is modular and always learning. As new research, trials or IP appear, the system updates its understanding and explains the drivers behind a shift. Inside the team we are also preparing a safe sandbox where we can test frontier reasoning systems on synthetic biotech tasks before they touch real decisions.
Embracing AI's Scale
Advanced AI-driven Analysis
We have built ContraNova, an AI engine that autonomously analyzes biotech companies to estimate success probabilities, surface investment opportunities, and uncover signals that traditional diligence often misses. Our engine is more accurate than GPT-5, and backtested on real outcomes.
Comprehensive Market Intelligence
ContraNova can search biotech startups across the web, score them with standardized, interpretable metrics, weigh backtested factors, assign success probabilities, and assess team backgrounds, all in one system. The platform reconstructs leading VC portfolios and predicts analyst ratings and private exits from automated reads of press releases, papers, clinical filings, and bios.
Time and Resource Efficiency
By automating data collection and analysis, ContraNova saves valuable time and resources. Our engine runs on 100+ interpretable biotech variables (pipeline ~21%, regulatory ~17%, etc.), so users can quickly access synthesized insights and focus on strategy, not data processing.
Specialized Databases for Precision
ContraNova leverages curated, specialized databases to provide highly relevant and up-to-date information. This targeted approach ensures that users receive the most precise data for their specific needs, supporting more accurate predictions and decisions.
Insights for Informed Decision-Making
Our system delivers tailored insights, adapting to the unique requirements of each user, pharma, investors, or researchers. With R² = 0.74 for analyst ratings and R² = 0.85 for private exits, ContraNova aids in more informed, strategic decision-making based on automated, interpretable analysis.
Competitive Edge
In fast-moving biotech, having up-to-date and comprehensive intelligence is crucial. ContraNova gives users a competitive advantage by providing the latest data and insights, helping them stay ahead in a dynamic market. We’re actively building with funds and adding new capabilities, let us know what would move the needle for you!
What our clients say
“Companies can use AI internally to enhance business operations such as procurement. A data unification software, uses machine learning to clean, analyze, and sort procurement data.”
Paul Schwimmer
CEO @ Precision Immunology Institute, USA
“Companies can use AI internally to enhance business operations such as procurement. A data unification software, uses machine learning to clean, analyze, and sort procurement data.”
Paul Schwimmer
CEO @ Precision Immunology Institute, USA
Subscribe to our newsletter
Receive our latest news, content, and upcoming events
We promise no spam; you’ll receive quarterly downloads of our updates as well as press releases.
I agree to the Terms of Service